DTRA Archives - EverGlade Consulting

DTRA

handheld diagnostic device

Assay Expansion for Chemical Diagnostic System

Assay-Expansion-for-Chemical-Diagnostics-System-SOO_Final The Defense Threat Reduction Agency’s Medical Diagnostics Branch (RD-CBMD) is driving innovation with its 2026 solicitation to expand the ChemDx platform. ChemDx is a handheld diagnostic device for rapid detection of chemical threats, such as nerve agents or certain pesticides, in blood from a finger prick. This effort seeks proposals from organizations interested in […]

Assay Expansion for Chemical Diagnostic System Read More »

technology to identify novel antigens

DTRA MCDC RAIIC Funding Opportunity

Final-draft-SOO-RAIIC The Joint Science and Technology Office (JSTO) Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC) to develop technologies that can accelerate the identification and immune profile of novel antigens in emerging infectious diseases (EID). JSTO intends to incorporate the final technology into

DTRA MCDC RAIIC Funding Opportunity Read More »

compact wearable vaccine monitoring

DTRA Issues Draft SOO for Continual Blood Sampling Technology

Final-Draft-SOO-IMMIR The Joint Science and Technology Office (JSTO) within the Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC). The objective of the IMMIR solicitation is to develop innovative technologies for vaccine monitoring via a compact wearable device that can analyze minute blood samples.

DTRA Issues Draft SOO for Continual Blood Sampling Technology Read More »

medical countermeasures

DTRA Issues SOO for Broad-Spectrum Therapeutics

August-24-Broad-Spectrum-SOO The Defense Threat Reduction Agency (DTRA) has released a Statement of Objectives (SOO) to develop  prototype Medical Countermeasures (MCMs) aimed at addressing therapeutic indications of Warfigher exposure to viral and bacterial biothreat agents. Key Information and Deadlines The Project Agreement Holder must state if their proposal is for the solution of the objecties of

DTRA Issues SOO for Broad-Spectrum Therapeutics Read More »

Scroll to Top
Flask with blue light

Webinar: R&D Funding in Life Sciences: What's Ahead in Trump 2.0?

Join us on Jan 15, 2025, at 12:00pm ET for a deep dive into the future of R&D Funding in Life Sciences.